WHO Global Diabetes Report 2025: Key Findings for Patients

The Biggest Diabetes Report in a Generation

In 2025, the World Health Organization released its most comprehensive global diabetes assessment to date, painting a striking picture of a condition that has quietly become one of the defining health crises of the 21st century. The findings are sobering — but they also highlight where medicine is advancing fastest and what patients can realistically expect in the years ahead. The headline figure is stark: approximately 830 million people worldwide are now living with diabetes, more than double the number recorded in 1990. Critically, the WHO report found that over 59% of adults with diabetes in low- and middle-income countries are receiving no treatment at all — a gap the report describes as a "preventable catastrophe."

Key Findings: What the Report Actually Says

Type 2 diabetes is driving the surge. Type 2 diabetes accounts for around 96% of all diabetes cases globally. The WHO attributes the rise to a combination of urbanization, ultra-processed food availability, physical inactivity, and aging populations. No single country is immune — rates have risen in every WHO region since 1990. Treatment access is profoundly unequal. The report found that while high-income countries have seen meaningful improvements in blood pressure and cholesterol control among people with diabetes, access to even basic insulin remains inadequate in dozens of countries. The WHO specifically called out the cost of analog insulins as a barrier to global care, noting that human insulin — significantly cheaper — remains underutilized despite being effective for many patients. Obesity is now the single largest modifiable risk factor. The report reinforces data from studies like the SCALE trial program (Novo Nordisk's semaglutide obesity trials) and the SELECT cardiovascular outcomes trial, which demonstrated that GLP-1 receptor agonists reduce major cardiovascular events by 20% in people with overweight or obesity and established cardiovascular disease — even without a diabetes diagnosis. This has fundamentally shifted how the WHO frames prevention. Early detection remains a crisis. An estimated 240 million people are living with undiagnosed type 2 diabetes globally. The WHO is calling for systematic HbA1c screening programs in primary care worldwide, citing evidence that early intervention dramatically reduces the risk of complications including kidney failure, blindness, and amputation.

GLP-1 Medications: The Report's Cautious Optimism

The WHO report dedicates significant attention to GLP-1 receptor agonists — drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — acknowledging their "remarkable efficacy" while expressing concern about global access and cost. The SURMOUNT trial program for tirzepatide showed up to 22.5% body weight reduction, results that the WHO acknowledges represent a genuine shift in what's pharmacologically possible for obesity-driven type 2 diabetes. However, the report explicitly notes that these medications are currently accessible to a small fraction of patients globally, and calls on manufacturers and governments to develop pricing frameworks that expand access — particularly in middle-income countries where diabetes rates are rising fastest.

Current Status (2025)

The WHO 2025 report is an assessment document, not a clinical trial — but its recommendations carry significant policy weight. As of 2025, the WHO is formally recommending that GLP-1 receptor agonists be considered for inclusion on national essential medicines lists in countries that can support them. This is a meaningful policy shift that could influence how health systems fund these treatments. For people with type 1 diabetes, the report acknowledges the promise of emerging therapies — including beta cell replacement approaches being studied in trials like Vertex's VX-880 program and the PROTECT trial evaluating teplizumab — but correctly notes these remain investigational. Patients interested in participating in active trials can search ClinicalTrials.gov using terms like "type 1 diabetes beta cell" or "islet transplant" to find studies currently enrolling. For everyday diabetes management in 2025, continuous glucose monitors, insulin pumps, and structured self-management remain the cornerstone of care. Resources like mdsdiabetes.com provide access to current monitoring technology and supplies that reflect today's evidence-based standard of care.

What This Means for Patients

If you have Type 2 diabetes: The WHO report strengthens the case for discussing GLP-1 medications with your doctor if you haven't already — particularly if you have cardiovascular risk factors. The SELECT trial data showing cardiovascular benefit is now part of mainstream clinical guidance. If you have Type 1 diabetes: The report is honest that transformative therapies like beta cell replacement are still years from routine availability. Stay current, ask your endocrinologist about trial eligibility, and focus on optimizing the excellent technology available today. If you're at risk: The report's most actionable message for pre-diabetic patients is that lifestyle intervention works. The landmark Diabetes Prevention Program trial — now with over 20 years of follow-up data — continues to show that modest weight loss and increased physical activity reduce progression to type 2 diabetes by up to 58%.

Timeline: When Will Things Change?

The WHO's recommendations influence national health policy over a 3–7 year horizon. GLP-1 access is likely to expand in middle-income countries within that window if pricing negotiations succeed. Truly curative therapies for type 1 diabetes — if current trials succeed — are realistically 5–10 years from widespread availability. The honest message from this report is that prevention and optimized management of existing disease remain the most powerful tools available right now.